Stockreport

SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors i...

Corbus Pharmaceuticals Holdings, Inc.  (CRBP) 
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: corbuspharma.com
PDF An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for efficacySYS6002 (CRB-701) demonstrated 44% ORR and [Read more]